Note that a meta-analysis performed on mCRC suggests that patients with left-sided RAS wt tumours achieve a benefit from being treated with chemotherapy plus EGFR antibody therapy, while our study population received cetuximab-based treatment combined, or not, with chemotherapy [34]. The gene discussed is EGFR; the disease is neoplasm.